Morningstar

Inside Information: Faron to Advance Bexmarilimab into a Registrational Phase 2/3 Study in Treatment-Naïve (frontline) HR-MDS after Positive Meeting with the FDA

TURKU, FI / ACCESS Newswire / August 18, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel ...
Morningstar

Inside Information: Faron to Present Updated BEXMAB Data in Frontline HR-MDS to FDA; Complete Remission Rate Substantially Increased to 43%

Inside Information: Complete remission rate in frontline HR-MDS patients rose from 28% to 43% in latest data cut, confirming the deepening of responses over time. TURKU, FI / ACCESS Newswire / August ...
Business Insider

Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk ...

– Observed 79% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete response (CR)/marrow complete response (mCR) rate of 64% – – Observed 27% ...
Targeted Oncology

Oncologists Choose Top Goals and Therapies for Treating MDS

The MEDALIST trial was a phase 3 study with patients with ESA-refractory, low-risk MDS who require transfusions. In this ...
Seeking Alpha

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher ...

– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall ...
Nasdaq

Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights

– Announced updated positive interim data from the Phase 1B dose-expansion clinical trial of SL-172154 in combination with Azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) ...
Business Wire

Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic ...
Nasdaq

Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic ...
Business Insider

Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes ...

– Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously untreated HR-MDS and TP53m AML patients; successfully bridged responding TP53m AML patients to ...
PharmiWeb

Faron Pharmaceuticals Ltd: Half-Year Financial Results 1 January - 30 June 2025

Faron Pharmaceuticals Ltd (AIM: FARN, First North:FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in ...
Benzinga.com

MEI Pharma Begins Phase II Trial of Pracinostat, Vidaza in Frontline Myelodysplastic Syndrome

MEI Pharma, Inc. MEIP, an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patients have been dosed in a Phase II clinical trial of ...